Clarivate Enhances OFF-X with Pathway Maps to Accelerate Target Safety Assessments

Core Insights - Clarivate Plc has introduced Pathway Maps in its OFF-X platform, enhancing translational safety intelligence in drug development [1][3] - Over 30% of drug development failures are linked to safety issues, necessitating earlier identification of potential liabilities [1][2] - The integration of visual disease biology with comprehensive safety data allows researchers to make faster, more informed decisions [2][3] Company Overview - Clarivate is a global provider of transformative intelligence, offering data, insights, analytics, and workflow solutions across various sectors including Life Sciences & Healthcare [5] - The company aims to empower researchers with tools that streamline workflows and provide actionable insights to improve patient outcomes [3][5] Product Features - OFF-X supports researchers throughout the drug development lifecycle, from early discovery to post-marketing surveillance [4] - The platform combines proprietary physiological and disease pathway visualizations with curated safety data, enhancing risk evaluation [3][4] - The addition of Pathway Maps allows for disease-specific visualizations of key signaling pathways, facilitating quicker identification of safety liabilities [2][3]